Skip to main content
padlock icon - secure page this page is secure

DARPins Bioengineering and its Theranostic Approaches: Emerging Trends in Protein Engineering

Buy Article:

$68.00 + tax (Refund Policy)

The therapeutic significance of bioengineering proteins has increased dramatically as a new generation of pharmacological drug with a great potential in medical treatment. Protein engineering has improved the use of new non immunoglobulin affinity proteins. The designed ankyrin repeat proteins abbreviated as DARPins is a classical example. These molecules have smaller structural size, unlike immunoglobulins, but similar target affinity is of great significance. Such molecules get more binding specificity and greater thermodynamic stability. These attributes made DARPins a favorite player in diagnostics and therapeutics of cancer. How DARPins are improved into vigorous and versatile scaffold for binding protein and selected by ribosome and phage display along with related aspects is discussed in this review.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Designed ankyrin repeat proteins; Protein bioengineering; Therapeutics

Document Type: Research Article

Publication date: March 1, 2017

More about this publication?
  • Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

    Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more